To our surprise, 80% of patients who did not respond to BVZ treatment had increased or no change in VEGF expression after treatment, as shown in Figure 6A, while 60% of GBM patients who responded to BVZ treatment had increased VEGF expression, as shown in Figure 6B. As can be seen in the figure, there is a more than 10-fold difference in VEGF expression before and after BVZ treatment in both the subtypes that respond to BVZ and those that do not respond to BVZ, so in this sample size there is no significant difference between the two subtypes before and after BVZ treatment. Here, VEGFA is linked to glioblastoma.